Schaeffer's Top Stock Picks for '25

Biotech Roundup: 3 Stocks to Watch

Checking in with REGN, INCY, and VRTX

Deputy Editor
Dec 11, 2024 at 3:35 PM
facebook X logo linkedin


Most recently in the ever-growing biotech industry, investors are musing over potential changes to the sector after President-elect Donald Trump picked Martin “Marty” Makary to be the U.S. Food and Drug Administration's (FDA) next commissioner, and Robert F. Kennedy Jr. to lead the Department of Health and Human Services. Today, we'll check checking in with three heavy-hitting biotech stocks and how they've been faring on the charts. 

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) stock is finally on the rebound, after a long-term pullback from its Aug. 27, record high of $1,211.20. The equity has been steadily moving higher since mid-November amid a series of updates, including positive data for the company's odronextamab monotherapy. REGN is flat at $778.39 today, despite BofA Global Research yesterday reinstating its "underperform" rating. Shares are down 11.4% in 2024.

Pharmaceutical stock Incyte Corp (NASDAQ:INCY) was last seen up 0.5% at $72.82, just above newfound support at the $72 level. The shares hit a Nov. 8, 52-week high of $83.95 before chopping lower, and still sport a 15.8% year-to-date lead. Yesterday, the company announced positive late-stage trial results for tafasitamab, a treatment for relapsed or refractory follicular lymphoma. 

Shares of Vertex Pharmaceuticals Inc (NASDAQ:VRTX) fell sharply after their Nov. 8 record high of $519.88, though the $450 region kept losses in check. Last seen down near breakeven at $469.39, the stock is up is up 15.2% since the start of the year. Jefferies upgraded VRTX to "buy" last session, citing huge growth potential. 

 
 

You have the chance to join one of Bernie's most exclusive programs, complete access at HUGE savings!

As we prepare for a new administration to take the reins in Washington, the near-term market landscape is rife with uncertainty.

The Federal Reserve has already hinted at the turbulence ahead, lowering its interest rate outlook for 2025.

Meanwhile, breakthroughs in artificial intelligence (AI), quantum computing, and other transformative sectors have unlocked incredible profit potential.

But these opportunities are fleeting, and timing is everything. That's where Quick-Hit Trader comes in.

Quick-Hit Trader is designed for precision and speed, getting you in and out of the market in a flash. While other investors scramble to navigate volatile conditions, you'll have access to expertly curated trades that leverage these rapid shifts to deliver explosive profits in short order.

This is your chance to capitalize on the fast-moving market like never before. Are you ready to make your move?